Postoperative atrial fibrillation (POAF) is a major complication of cardiac surgery, which
could lead to high morbidity and mortality, increase duration of hospital stay and increase
the cost of treatment. Colchicine possesses both anti-inflammatory and sympatholytic
properties, so it has been studied to prevent POAF. The ACC/AHA guidelines for colchicine
contain a class IIB recommendation, but the ESC guidelines do not recommend this drug. More
researches are needed to focus on reducing of side effects by optimizing the colchicine
regimen to reduce the incidence of gastrointestinal side effects. It is believed that further
research is needed to investigate the efficacy and safety of colchicine in these conditions.
This research is aimed to study the effectiveness of short-term administration of the drug.
Phase:
Phase 4
Details
Lead Sponsor:
Bakulev Scientific Center of Cardiovascular Surgery